XML 37 R23.htm IDEA: XBRL DOCUMENT
v3.25.3

Debt | 12 Months Ended
--- | ---
Sep. 30, 2025
Debt Disclosure [Abstract] |
Debt | Debt Current debt obligations The carrying value of Current debt obligations, net of unamortized debt issuance costs, at September 30 consisted of:
(Millions of dollars) |  |  | 2025 |  | 2024
Commercial paper borrowings |  |  | $ | 855 |  |  | $ | 400 |
Current portion of long-term debt |  |  |  |  |
3.734% Notes due December 15, 2024 | (a) |  | — |  |  | 875 |
3.020% Notes due May 24, 2025 | (a) |  | — |  |  | 335 |
0.034% Notes due August 13, 2025 | (a) |  | — |  |  | 559 |
1.208% Notes due June 4, 2026 |  |  | 704 |  |  | — |
Other |  |  | 1 |  |  | 1 |
Total current debt obligations |  |  | $ | 1,560 |  |  | $ | 2,170 |
(a)All of the aggregate principal amount outstanding was retired upon maturity during fiscal 2025, as further discussed below. The weighted average interest rates for current debt obligations were 2.89% and 2.91% at September 30, 2025 and 2024, respectively. From time to time, the Company may access the commercial paper market as it manages working capital over the normal course of its business activities. The Company’s U.S. and multicurrency euro commercial paper programs provide for a maximum amount of unsecured borrowings under the two programs, in aggregate, of $2.750 billion. Proceeds from these programs may be used for working capital purposes and general corporate purposes, which may include acquisitions, share repurchases, and repayments of debt. The Company utilized commercial paper borrowings in the fourth quarter of fiscal year 2024 to partially fund the Advanced Patient Monitoring acquisition, as further discussed in Note 11. Long-term debt The carrying value of Long-Term Debt, net of unamortized debt issuance costs, at September 30 consisted of:
(Millions of dollars) |  |  | 2025 |  | 2024
1.208% Notes due June 4, 2026 |  |  | — |  |  | 671 |
6.700% Notes due December 1, 2026 |  |  | 154 |  |  | 158 |
1.900% Notes due December 15, 2026 |  |  | 586 |  |  | 559 |
3.700% Notes due June 6, 2027 |  |  | 1,722 |  |  | 1,721 |
7.000% Debentures due August 1, 2027 |  |  | 117 |  |  | 118 |
4.693% Notes due February 13, 2028 |  |  | 798 |  |  | 797 |
6.700% Debentures due August 1, 2028 |  |  | 114 |  |  | 115 |
0.334% Notes due August 13, 2028 |  |  | 1,054 |  |  | 1,004 |
4.874% Notes due February 8, 2029 |  |  | 622 |  |  | 622 |
5.081% Notes due June 7, 2029 |  |  | 597 |  |  | 596 |
3.553% Notes due September 13, 2029 |  |  | 936 |  |  | 891 |
2.823% Notes due May 20, 2030 |  |  | 747 |  |  | 746 |
3.519% Notes due February 8, 2031 |  |  | 876 |  |  | 835 |
1.957% Notes due February 11, 2031 |  |  | 995 |  |  | 994 |
3.828% Notes due June 7, 2032 |  |  | 1,168 |  |  | 1,113 |
4.298% Notes due August 22, 2032 |  |  | 496 |  |  | 496 |
5.110% Notes due February 8, 2034 |  |  | 546 |  |  | 545 |
1.213% Notes due February 12, 2036 |  |  | 701 |  |  | 668 |
4.029% Notes due June 7, 2036 |  |  | 933 |  |  | 889 |
6.000% Notes due May 15, 2039 |  |  | 121 |  |  | 121 |
5.000% Notes due November 12, 2040 |  |  | 90 |  |  | 90 |
1.336% Notes due August 13, 2041 |  |  | 1,049 |  |  | 999 |
4.875% Notes due May 15, 2044 |  |  | 244 |  |  | 244 |
4.685% Notes due December 15, 2044 |  |  | 938 |  |  | 934 |
4.669% Notes due June 6, 2047 |  |  | 1,462 |  |  | 1,460 |
3.794% Notes due May 20, 2050 |  |  | 554 |  |  | 554 |
Other long-term debt |  |  | 1 |  |  | 1 |
Total Long-Term Debt |  |  | $ | 17,621 |  |  | $ | 17,940 |
The aggregate annual maturities of Long-Term Debt including interest during the fiscal years ending September 30, 2026 to 2030 are as follows: 2026 — $2.228 billion; 2027 — $3.163 billion; 2028 — $2.486 billion; 2029 — $2.629 billion; 2030 — $1.144 billion. Other current credit facilities During the fourth quarter of fiscal year 2025, the Company refinanced its existing senior unsecured revolving credit facility, which was scheduled to mature in September 2027, with a new senior unsecured revolving credit facility maturing in September 2030. The credit facility provides borrowings of up to $2.750 billion, with separate sub-limits of $100 million and $236 million for letters of credit and swingline loans, respectively. The expiration date of the credit facility may be extended for up to two additional one-year periods, subject to certain restrictions, including the consent of the lenders. The credit facility provides that the Company may, subject to additional commitments by lenders, request an additional $500 million of financing, for a maximum aggregate commitment under the credit facility of up to $3.250 billion. Proceeds from this facility may be used for general corporate purposes and Becton Dickinson Euro Finance S.à r.l. (“Becton Finance”), an indirect, wholly-owned finance subsidiary of BD, is authorized as an additional borrower under the credit facility. There were no borrowings outstanding under either credit facility as of September 30, 2025 and 2024. In addition, the Company has informal lines of credit outside of the United States. Debt issuances The Company issued the following U.S. dollar-denominated debt during fiscal year 2024:
Interest rate and maturity |  | Period issued |  | Amount issued (Millions of dollars) |  | Use of proceeds
5.081% Notes due June 7, 2029 |  | Third quarter 2024 |  | $ | 600 |  |  | Funding of the cash consideration and related fees and expenses for the Advanced Patient Monitoring acquisition and for general corporate purposes
4.874% Notes due February 8, 2029 |  | Second quarter 2024 |  | $ | 625 |  |  | Retirement of 3.363% notes due June 6, 2024 and retirement, upon maturity, of 3.734% notes due December 15, 2024
5.110% Notes due February 8, 2034 |  | Second quarter 2024 |  | $ | 550 |  |  | Retirement of 3.363% notes due June 6, 2024 and retirement, upon maturity, of 3.734% notes due December 15, 2024
The Company issued the following Euro-denominated debt during fiscal year 2024:
Interest rate and maturity |  | Period issued |  | Amount issued (Millions of Euros) |  | Amount issued (Millions of dollars) |  | Use of proceeds
3.828% Notes due June 7, 2032 |  | Third quarter 2024 |  | € | 1,000 |  |  | $ | 1,087 |  |  | Funding of the cash consideration and related fees and expenses for the Advanced Patient Monitoring acquisition and for general corporate purposes
3.519% Notes due February 8, 2031 |  | Second quarter 2024 |  | € | 750 |  |  | $ | 806 |  |  | Retirement of 3.875% notes due May 15, 2024 and 3.363% notes due June 6, 2024
Also in fiscal year 2024, Becton Finance issued Euro-denominated notes, listed below, which are fully and unconditionally guaranteed on a senior unsecured basis by the Company. No other of the Company’s subsidiaries provide any guarantees with respect to these notes. The indenture covenants included a limitation on liens and a restriction on sale and leasebacks, change of control and consolidation, merger and sale of assets covenants. These covenants are subject to a number of exceptions, limitations and qualifications. The indenture does not restrict the Company, Becton Finance, or any other of the Company’s subsidiaries from incurring additional debt or other liabilities, including additional senior debt. Additionally, the indenture does not restrict Becton Dickinson Euro Finance S.à r.l. and the Company from granting security interests over its assets. The notes issued by Becton Finance included the following:
Interest rate and maturity |  | Period issued |  | Amount issued (Millions of Euros) |  | Amount issued (Millions of dollars) |  | Use of proceeds
4.029% Notes due June 7, 2036 |  | Third quarter 2024 |  | € | 800 |  |  | $ | 869 |  |  | Funding of the cash consideration and related fees and expenses for the Advanced Patient Monitoring acquisition and for general corporate purposes
Debt retirements The Company’s retirements of debt upon maturity in fiscal years 2025 and 2024 included the following:
Principal, interest rate, and maturity |  | Period of retirement |  |  |  |  |  |
€500 million ($584 million) of 0.034% notes due August 13, 2025 |  | Fourth quarter 2025 |  |  |  |  |  |
£250 million ($339 million) of 3.020% notes due May 24, 2025 |  | Third quarter 2025 |  |  |  |  |  |
$875 million of 3.734% notes due December 15, 2024 |  | First quarter 2025 |  |  |  |  |  |
$998 million of 3.363% notes due June 6, 2024 |  | Third quarter 2024 |  |  |  |  |  |
$144 million of 3.875% notes due May 15, 2024 |  | Third quarter 2024 |  |  |  |  |  |
Capitalized interest The Company capitalizes interest costs as a component of the cost of construction in progress. A summary of interest costs and payments for the years ended September 30 is as follows:
(Millions of dollars) | 2025 |  | 2024 |  | 2023
Charged to operations | $ | 613 |  |  | $ | 528 |  |  | $ | 452 |
Capitalized | 62 |  |  | 57 |  |  | 51 |
Total interest costs | $ | 675 |  |  | $ | 584 |  |  | $ | 503 |
Interest paid, net of amounts capitalized | $ | 628 |  |  | $ | 473 |  |  | $ | 452 |

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details
Name: | us-gaap_DebtDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration